IVVD

Invivyd, Inc. (IVVD) 2024 Annual Report (10-K) Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2024. Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies (mAbs) for viral infectious diseases, primarily SARS-CoV-2. The company's lead product, PEMGARDA (pemivibart), received Emergency Use Authorization (EUA) from the FDA in March 2024 for the pre-exposure prophylaxis of COVID-19 in immunocompromised adults and adolescents. The company is also advancing VYD2311, a next-generation mAb candidate, which completed Phase 1 recruitment in February 2025 with positive safety and pharmacokinetic data.

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The filing text does not provide a specific gross margin percentage, though management noted that if pre-EUA manufacturing costs had been capitalized, reported margins would approach 80%.

Material Changes vs. Prior Period

• Revenue Generation: The company transitioned from zero revenue in 2023 to $25.4 million in 2024 following the March 2024 EUA launch of PEMGARDA.
• Expense Reduction: Total operating expenses decreased by $10.5 million to $202.3 million. R&D expenses declined by $21.4 million, primarily due to reduced costs for the pemivibart program (commercial manufacturing and Phase 3 trial costs) partially offset by increased investment in the VYD2311 program.
• SG&A Increase: SG&A expenses increased by $14.3 million, driven by commercialization costs for PEMGARDA and accelerated stock-based compensation related to the departure of the former CEO.
• Cash Position: Cash and cash equivalents decreased by approximately $131.3 million, reflecting a net cash burn of $170.5 million from operating activities, partially offset by $39.3 million in net proceeds from an "at-the-market" equity offering.

Guidance, Outlook, Risks, and Contingencies

• Going Concern Warning: The company has concluded there is substantial doubt about its ability to continue as a going concern. Based on current plans, cash reserves ($69.3 million) are insufficient to fund operations beyond one year from the issuance of the financial statements without additional funding or significant revenue growth.
• Regulatory Risks:
  • EUA Limitations: PEMGARDA's EUA is contingent on the national frequency of resistant variants remaining below 90%. The FDA declined a request in February 2025 to expand the EUA to cover treatment of mild-to-moderate COVID-19.
  • Variant Evolution: Emerging SARS-CoV-2 variants could reduce the efficacy of PEMGARDA, potentially leading to EUA revocation.
• Manufacturing Concentration: The company relies exclusively on a single contract manufacturer, WuXi Biologics (China-based), for all clinical and commercial supply. This exposes the company to geopolitical risks, including potential U.S. legislation (e.g., BIOSECURE Act) targeting Chinese biotechnology firms.
• Capital Needs: The company expects to require additional funding through equity offerings, debt, or collaborations to sustain operations and commercialization efforts.
• Market Acceptance: Commercial success depends on third-party payer reimbursement and physician adoption, which may be impacted by the boxed warning for anaphylaxis associated with PEMGARDA.

Key Facts for Investor Verification

• Liquidity Runway: Verify the company's ability to secure additional capital within the next 12 months given the "substantial doubt" going concern qualification.
• PEMGARDA Sales Trajectory: Monitor quarterly revenue trends to assess if sales are sufficient to offset operating burn rates.
• Variant Surveillance Data: Track independent virology data regarding PEMGARDA's neutralizing activity against emerging variants (e.g., XEC, LP.8.1) to assess EUA stability.
• Manufacturing Supply Chain: Monitor legislative developments regarding the BIOSECURE Act and potential impacts on the WuXi Biologics partnership.
• VYD2311 Progress: Watch for Phase 1 data readouts in 2025 to determine the viability of the next-generation pipeline.